Sign inJoin waitlistJoin the waitlist

Wajeeha Razaq

Site Chair for Breast Cancer · OU Health Stephenson Cancer Center

Credentials: · · · · · ·

History

OU Health Stephenson Cancer Center
Present
University of Oklahoma College of Medicine
Present

Hematology and Medical Oncology
Hematology/Oncology Mount Sinai Roosevelt Hospital
2005–2008
Internal Medicine
Internal Medicine Sunny Downstate Long Island College Hospital
2002–2005
Pediatrics
Mayo Clinic
1999–2002
King Edward Medical University
1995–1999

Research

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology · 2022 · 385 citations
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)
Journal of Clinical Oncology · 2022 · 161 citations
The effect of soluble E-selectin on tumor progression and metastasis
BMC Cancer · 2016 · 44 citations

Priya Rastogi
2 papers
SS
Sufana Shikdar
2 papers · 2 as a fellow
Abigail Caudle
1 paper
AB
Adam Brufsky
1 paper
Ajay Jain
1 paper
Albert Wendt
1 paper
Ali Amin
1 paper · 1 as a resident
Amy Tiersten
1 paper
Amye Tevaarwerk
1 paper
Ana Condacse
1 paper
AS
Andrea Silber
1 paper
Ann Partridge
1 paper

Clinical trials

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033